Cavalier Investments’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Cavalier Investments’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-24,164	Closed	-$3.28M	–	118
2021 Q1	$3.28M	Buy	24,164 +1,856	+8%	+$278K	1.43%	17
2020 Q4	$3.14M	Sell	22,308 -2,692	-11%	-$345K	1.44%	23
2020 Q3	$2.79M	Buy	+25,000	New	+$2.8M	1.89%	15
2018 Q3	–	Sell	-40,558	Closed	-$3.86M	–	187
2018 Q2	$3.86M	Buy	40,558 +38,869	+2,301%	+$3.57M	1.3%	10
2018 Q1	$148K	Sell	1,689 -34,556	-95%	-$3.15M	0.05%	146
2017 Q4	$3.08M	Buy	+36,245	New	+$3.04M	1.23%	24

Other funds holding XBI

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Cavalier Investments's XBI Position: Q2 2021 in Review

Cavalier Investments sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2021, closing a stake of 24,164 shares — an estimated $3.28M sold.

Cavalier Investments first reported a position in XBI in Q4 2017 and held it in 6 quarters. The position peaked at $3.86M in Q2 2018. 663 funds tracked by Wall St. Rank hold XBI as of Q2 2021.

Cavalier Investments reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2021 after selling out during the quarter.
Cavalier Investments sold 24,164 State Street SPDR S&P Biotech ETF shares in Q2 2021, an estimated $3.28M.
Cavalier Investments first reported a position in State Street SPDR S&P Biotech ETF in Q4 2017 and held it in 6 quarters.
Cavalier Investments's State Street SPDR S&P Biotech ETF position peaked at $3.86M in Q2 2018.
663 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2021.

Based on Cavalier Investments's 13F filing for Q2 2021, filed 11 Aug 2021.